Spots Global Cancer Trial Database for papillomavirus vaccines
Every month we try and update this database with for papillomavirus vaccines cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV | NCT05266898 | Papillomavirus ... Human Immunodef... Papillomavirus ... Serology Cervical Intrae... Anal Intraepith... Oral Cavity Inf... | Human papilloma... | 18 Years - 45 Years | Louisiana State University Health Sciences Center in New Orleans | |
| Let's K-Talk - HPV Study for Ethnic Koreans | NCT05884697 | Human Papilloma... Papillomavirus ... | K-Talk Interven... Storytelling In... K-Bot Intervent... Written Informa... | 18 Years - 45 Years | University of Cincinnati | |
| A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults | NCT00798265 | Human Immunodef... Human Papilloma... Adolescent Papillomavirus ... | Gardasil Survey | 12 Years - 26 Years | National Institutes of Health Clinical Center (CC) | |
| Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination | NCT03350698 | Papillomavirus ... | Gardasil-9 | 27 Years - 69 Years | Eastern Virginia Medical School | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 | NCT03848039 | Cervical Intrae... | Gardasil-9 Placebo | 18 Years - | Azienda USL Toscana Nord Ovest | |
| Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors | NCT04469569 | Papillomavirus ... | HPV-PROTECT | 9 Years - | University of Alabama at Birmingham | |
| An Intervention Promoting HPV Vaccination in Safety-net Clinics | NCT01729429 | Human Papilloma... | HPV brochure, r... General Adolesc... | 11 Years - 18 Years | University of Texas Southwestern Medical Center | |
| Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | NCT01031069 | Infections, Pap... Papillomavirus ... | GSK Biologicals... Merck's Human P... | 15 Years - 25 Years | GlaxoSmithKline | |
| Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors | NCT04469569 | Papillomavirus ... | HPV-PROTECT | 9 Years - | University of Alabama at Birmingham | |
| Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination | NCT03501992 | Papillomavirus ... | Current care Reminder-recall Audit-and-feedb... Combined remind... | 11 Years - 12 Years | Mayo Clinic | |
| Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 | NCT03848039 | Cervical Intrae... | Gardasil-9 Placebo | 18 Years - | Azienda USL Toscana Nord Ovest | |
| An Intervention Promoting HPV Vaccination in Safety-net Clinics | NCT01729429 | Human Papilloma... | HPV brochure, r... General Adolesc... | 11 Years - 18 Years | University of Texas Southwestern Medical Center | |
| A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine | NCT03900572 | HPV Infections | HPV Vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination | NCT03501992 | Papillomavirus ... | Current care Reminder-recall Audit-and-feedb... Combined remind... | 11 Years - 12 Years | Mayo Clinic | |
| Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination | NCT03350698 | Papillomavirus ... | Gardasil-9 | 27 Years - 69 Years | Eastern Virginia Medical School | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | NCT00294047 | Infections, Pap... Papillomavirus ... | Cervarix Placebo control | 26 Years - | GlaxoSmithKline | |
| Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | NCT05580341 | Cervical Cancer Genital Wart CIN VIN Papillomavirus ... | Zerun HPV-9 GARDASIL ®9 | 16 Years - 26 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. | NCT00877877 | Infections, Pap... Papillomavirus ... | Blood sampling | 15 Years - 24 Years | GlaxoSmithKline | |
| Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors | NCT04469569 | Papillomavirus ... | HPV-PROTECT | 9 Years - | University of Alabama at Birmingham | |
| Effectiveness of HPV Vaccine in Thai Adult Women | NCT03763565 | Uterine Cervica... Papillomavirus ... | Bivalent or Qua... Control group | 25 Years - 53 Years | Mahidol University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
